Story perspectives

NewLimit Secures $435M, Valued at $3.1B for Liver-Age Drug

6/3/2026

Summary

NewLimit Raises

NewLimit, co-founded by Coinbase CEO Brian Armstrong, raised $435 million in a Series C round on June 3 2026.
The financing, led by Founders Fund and joined by Kleiner Perkins, Eli Lilly Ventures, Thrive, Greenoaks and Quiet Capital, lifted valuation to $3.1 billion, over three times the prior level.
NewLimit will use the proceeds to expand labs, scale production and prepare a 2027 trial of its transcription-factor lipid-nanoparticle drug that reverses liver-cell age in alcohol-related disease.

Summary

NewLimit Reverses Aging

NewLimit delivers messenger RNA in lipid nanoparticles to liver cells, prompting proteins that reverse age-related decline.
Its core technology uses epigenetic reprogramming to restore youthful behavior in aging cells without changing DNA.
The firm screens thousands of transcription-factor combos with high-throughput assays to find rejuvenating factors.
Preclinical tests showed treated aged human liver cells expressed younger markers, cutting the human-trial timeline from over ten years to under a decade.

History

Historical Context

Andrew Fire and Craig Mello uncovered RNA interference in 1998, showing double-stranded RNA can silence genes; their work earned the 2006 Nobel Prize. The mechanism spurred therapeutic siRNA development, culminating in the FDA’s 2018 approval of Alnylam’s lipid-nanoparticle drug Onpattro for hereditary amyloidosis. This lineage underpins today’s mRNA-lipid nanoparticle platforms targeting age-related diseases.

1 of 3

NewLimit Raises

NewLimit, co-founded by Coinbase CEO Brian Armstrong, raised $435 million in a Series C round on June 3 2026.
The financing, led by Founders Fund and joined by Kleiner Perkins, Eli Lilly Ventures, Thrive, Greenoaks and Quiet Capital, lifted valuation to $3.1 billion, over three times the prior level.
NewLimit will use the proceeds to expand labs, scale production and prepare a 2027 trial of its transcription-factor lipid-nanoparticle drug that reverses liver-cell age in alcohol-related disease.

1 / 3